大葉大學圖書館 |

登入

回首頁

Interleukin 12[electronic resource] ...

Lasek, Witold.

Interleukin 12[electronic resource] :antitumor activity and immunotherapeutic potential in oncology /

紀錄類型:	書目-電子資源 : Monograph/item
杜威分類號:	616.079
書名/作者:	Interleukin 12 : antitumor activity and immunotherapeutic potential in oncology // by Witold Lasek, Radoslaw Zagozdzon.
作者:	Lasek, Witold.
其他作者:	Zagozdzon, Radoslaw.
出版者:	Cham : : Springer International Publishing :, 2016.
面頁冊數:	vii, 75 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Interleukin-12.
標題:	Biomedicine.
標題:	Immunology.
標題:	Cancer Research.
標題:	Cytokines and Growth Factors.
標題:	Oncology.
標題:	Cell Biology.
ISBN:	9783319469065
ISBN:	9783319469058
摘要、提要註:	This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies)
電子資源:	http://dx.doi.org/10.1007/978-3-319-46906-5

Interleukin 12[electronic resource] :antitumor activity and immunotherapeutic potential in oncology /
Lasek, Witold.

Interleukin 12antitumor activity and immunotherapeutic potential in oncology /[electronic resource] :by Witold Lasek, Radoslaw Zagozdzon. - Cham :Springer International Publishing :2016. - vii, 75 p. :ill., digital ;24 cm. - SpringerBriefs in immunology,2194-2773. - SpringerBriefs in immunology..

This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies)

ISBN: 9783319469065

Standard No.: 10.1007/978-3-319-46906-5doiSubjects--Topical Terms:

670705
Interleukin-12.

LC Class. No.: QR185.8.I56

Dewey Class. No.: 616.079

Interleukin 12[electronic resource] :antitumor activity and immunotherapeutic potential in oncology /
LDR:01853nmm a2200313 a 4500 001 466107
003 DE-He213
005 20160923120258.0
006 m d
007 cr nn 008maaau
008 170415s2016 gw s 0 eng d
020 $a 9783319469065 $q (electronic bk.)
020 $a 9783319469058 $q (paper)
024 7 $a 10.1007/978-3-319-46906-5 $2 doi
035 $a 978-3-319-46906-5
040 $a GP $c GP
041 0 $a eng
050 4 $a QR185.8.I56
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
082 0 4 $a 616.079 $2 23
090 $a QR185.8.I56 $b L343 2016
100 1 $a Lasek, Witold. $3 670703
245 1 0 $a Interleukin 12 $h [electronic resource] : $b antitumor activity and immunotherapeutic potential in oncology / $c by Witold Lasek, Radoslaw Zagozdzon.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a vii, 75 p. : $b ill., digital ; $c 24 cm.
490 1 $a SpringerBriefs in immunology, $x 2194-2773
520 $a This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies)
650 0 $a Interleukin-12. $3 670705
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Immunology. $3 402223
650 2 4 $a Cancer Research. $3 463530
650 2 4 $a Cytokines and Growth Factors. $3 465271
650 2 4 $a Oncology. $3 205017
650 2 4 $a Cell Biology. $3 463594
700 1 $a Zagozdzon, Radoslaw. $3 670704
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a SpringerBriefs in immunology. $3 605200
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-46906-5
950 $a Biomedical and Life Sciences (Springer-11642)

筆 0 讀者評論

多媒體

多媒體檔案
http://dx.doi.org/10.1007/978-3-319-46906-5

評論

新增評論分享你的心得

Export

取書館別